TD Cowen raised the firm’s price target on Ultragenyx (RARE) to $73 from $61 and keeps a Buy rating on the shares. The firm updated its model and corresponding estimates in conjunction with its Q3 earnings preview.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx price target raised to $83 from $73 at BofA
- Inozyme appoints Erik Harris to board of directors
- Ultragenyx receives Breakthrough Therapy Designation for setrusumab
- Ultragenyx provides update on Cyprus2+ study, to submit protocol amendment
- Closing Bell Movers: Ultragenyx Pharmaceutical slips 2% on study update